A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
Completed
National Cancer Institute (NCI)
Phase 1
1997-07-01
Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a
1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan.
Postoperatively, patients will be treated with hepatic arterial infusion of floxuridine
(FUDR), 0.2 mg/kg/day and leucovorin (LV), 15 mg/M2/day as a 2-week continuous infusion
regimen. Hepatic and systemic toxicity, response to treatment, duration of response, and
survival will be followed.
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
Completed
National Cancer Institute (NCI)
Phase 3
1996-01-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more cancer cells. It is not
yet known which chemotherapy regimen is more effective for metastatic colorectal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine,
leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating
patients who have unresectable liver metastases from colorectal cancer.
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
Completed
Alliance for Clinical Trials in Oncology
Phase 3
1996-01-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more cancer cells. It is not
yet known which chemotherapy regimen is more effective for metastatic colorectal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine,
leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating
patients who have unresectable liver metastases from colorectal cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.